Constitutive gut-homing capacity on circulating myeloid dendritic cells in coeliac disease

Dear Editor,

Coeliac disease (CD) is a small intestine immune enteropathy to gluten-containing cereals developed in genetically (HLA-DQ2+) predisposed individuals resulting in a pro-inflammatory T-cell mediated duodenal response characterized by villous atrophy, crypt hyperplasia and increase infiltration of intraepithelial lymphocytes. Its only treatment is a permanent strict gluten-free diet (GFD) after which the immune response is abrogated leading to clinical remission of the disease (1).

Dendritic cells (DC), the most potent antigen presenting cells, control the type and location of immune responses by differentiating antigen-specific effector T-cells (2) and directing them to the target tissue via homing marker imprinting (3,4). DC are therefore central in CD pathogenesis as they present gluten antigen to T-cells in a HLA-DQ2 restricted manner generating gluten-specific pro-inflammatory gut-homing T-cells (5). DC themselves also express homing markers displaying a multi-homing potential in the blood from healthy controls (HC) (6). However, the homing marker profile of blood DC is altered during gut inflammation. Circulating DC from patients with Crohn’s disease had decreased expression of the skin homing molecule CLA rendering circulating DC with an increased β7+CLA- gut homing phenotype (7). Such findings suggest that assessing blood DC homing profile may be a useful diagnostic tool to assess the phenotype/status of such patients. However, as DC do not recirculate it is difficult to understand how they display altered homing profile trafficking them to the target tissue where the inflammation is ongoing. Indeed, such altered DC homing profile could be a constitutive factor of the disease or on the contrary be consequence of the ongoing gastrointestinal inflammation which has the capacity to modulate –via secreted cytokines– homing profile and homing-imprinting capacity of DC (8). To further our understanding in the mechanisms of the altered DC trafficking in gastrointestinal disease, here we assessed the homing profile of another small bowel condition, CD, focusing on GFD-treated patients.

Circulating DC were identified by flow cytometry as HLA-DR+CD3-CD14-CD16-CD19-CD34-. Myeloid (mDC) and putative plasmacytoid DC (pDC) were further identified as CD11c+ and CD11c- respectively (Fig. 1A). There was no difference in the percentage or type of circulating DC between HC (with not known autoimmune diseases or malignancies) and CD-GFD patients. In agreement with our previous findings circulating mDC from HC displayed a multi-homing β7+CLA+ phenotype (6). On the contrary, mDC from GFD-CD patients had decreased CLA expression (Fig. 1 B and C) rendering mDC with an increased gut homing β7+CLA- profile (Fig. 1C) as in small bowel Crohn’s disease (7). However, in contrast to Crohn’s disease patients, GFD-CD patients did not have an ongoing inflammation. All GFD-CD had negative serology and no clinical symptoms of disease. In addition, expression of innate immunity receptors TLR2/4 (Fig. 1D) and activation markers CD40/80 (Fig. 1E) on GFD-CD patients were not differentially expressed from those found in HC confirming the absence of an ongoing inflammation. All GFD-CD had negative serology and no clinical symptoms of disease. In addition, expression of innate immunity receptors TLR2/4 (Fig. 1D) and activation markers CD40/80 (Fig. 1E) on GFD-CD patients were not differentially expressed from those found in HC confirming the absence of an ongoing inflammation. Finally, altered homing profile remained restricted to the mDC population as no difference was found in the phenotype of circulating CD11c DC from HC and GFD-CD (data not shown).

Our results suggest that circulating mDC from CD patients have an increased gut-homing profile which does not seem to...
be a consequence of an inflammatory response of the disease but may be a constitutive characteristic of such patients. Such increased DC gut-homing capacity may have a role in the abnor-

mal response to gluten antigens in CD and could also be used as a diagnostic tool to help in CD diagnosis.

Acknowledgements

The author(s) gratefully acknowledge the support of the St Mark’s Hospital Foundation.

I. Comino\(^1\), T. Šuligoj\(^2\), H.O. Al-Hassi\(^3\), G.H. Lee\(^4\), C. Sousa\(^1\), J. Landy\(^5\), P. J. Ciclitira\(^2\), S.C. Knight\(^1\) and D. Bernardo\(^1\)

\(^1\)Department of Microbiology and Parasitology. Faculty of Pharmacy. University of Seville. Seville, Spain. \(^2\)King’s College London. Division of Diabetes and Nutritional Sciences. Gastroenterology. The Rayne Institute, St Thomas’ Hospital. United Kingdom. \(^3\)Antigen Presentation Research Group. Imperial College London. Harrow, United Kingdom. \(^4\)Department of Gastroenterology, St Mark’s Hospital. Harrow, United Kingdom

References